Melanotan II — Published Research

Melanotan II activates melanocortin-1 receptors (MC1R) on melanocytes, triggering Gαs-mediated cAMP accumulation. This activates protein kinase A (PKA), which phosphorylates CREB transcription factor, inducing MITF (microphthalmia-associated transcription factor) expression. MITF then upregulates melanogenic enzyme genes including tyrosinase, TRP-1, and TRP-2, resulting in increased eumelanin synthesis. MC1R variants (common in fair-skinned populations) show reduced cAMP response to α-MSH analogs.

Dorr RT et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996. PubMed

MT-II was designed using structure-activity relationship (SAR) optimization of the α-MSH pharmacophore. Critical modifications include: (1) cyclization via lactam bridge between Asp and Lys, conferring protease resistance and receptor selectivity; (2) substitution of Met⁴ with Nle (norleucine) preventing oxidation; (3) D-Phe⁷ substitution enhancing binding affinity. These modifications result in approximately 100-fold greater potency than linear α-MSH at MC1R and extended plasma half-life from minutes to hours.

Hruby VJ et al. “Structure-activity relationships and bioactivities of melanocortin analogs.” Ann N Y Acad Sci. 1995. PubMed

A single-blind, placebo-controlled phase 1 pilot study studied MT-II in healthy male volunteers. Skin pigmentation was measured by reflectance spectroscopy over 7 days post-dose. Pharmacokinetic analysis showed plasma levels with T_max of 1–2 hours. Skin melanin index showed significant increases compared to placebo. The study characterized the pigmentation response and documented the adverse event profile including nausea.

Dorr RT et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996. PubMed